Spatial Multi-omics and Intelligent Early Warning of Pancreatic Cancer Cachexia

Spatial Multi-omics Mechanism Analysis and Multimodal Intelligent Early Warning of Cachexia in Pancreatic Cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07670286

Enrollment

500

Registered

2026-06-26

Start date

2026-04-24

Completion date

2028-08-31

Last updated

2026-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cachexia; Cancer; Sarcopenia, Pancreatic Cancer

Keywords

Spatial Multi-omics, Multimodal intelligent, Pancreatic Cancer, Cachexia

Brief summary

The goal of this observational study is to explore the spatial multi-omics mechanism of cachexia in pancreatic cancer and construct a high-precision multimodal intelligent early warning model for its early diagnosis in pathologically confirmed pancreatic ductal adenocarcinoma patients aged ≥18 years with an expected survival of ≥1 month. The main questions it aims to answer are: 1) Can spatial transcriptomics/metabolomics reveal the interaction mechanism between tumor microenvironment and metabolism in pancreatic cancer cachexia? 2)Can a multimodal AI early warning model be built to achieve accurate early identification of pancreatic cancer cachexia? Researchers will compare the surgical cohort and advanced cohort to see the differences in cachexia incidence and progression rules among different subgroups. Participants will complete baseline questionnaires on physical and mental state, nutrition and muscle strength, undergo imaging examinations and provide biological samples (blood, feces, tissue etc.), and receive regular follow-ups for updated questionnaires, imaging rechecks and supplementary biological sample collection until death, loss to follow-up or voluntary withdrawal.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with pathologically confirmed pancreatic ductal adenocarcinoma. * Aged ≥18 years with an expected survival time of ≥1 month (to be assessed for the advanced cohort). Assessment criteria: Comprehensive evaluation based on the patient's radiological tumor burden, vital organ function and physical status. Specific quantitative indicators: Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2, or Karnofsky Performance Status (KPS) score of ≥60. For patients in the advanced cohort, the assessment shall be jointly confirmed by two attending physicians with the professional title of associate chief physician or above in combination with radiological examination results. * Voluntarily sign the informed consent form.

Exclusion criteria

* Complicated with other untreated malignant tumors or severe mental disorders. * Pregnant women or patients unable to cooperate with follow-up.

Design outcomes

Primary

Measure	Time frame
Overall Survival	Time from enrollment to all-cause death, assessed up to 3 years.

Secondary

Measure	Time frame
Cachexia-free survival	Time from enrollment to cachexia diagnosis, assessed up to 3 years.

Countries

China

Outcome results